Progress Toward Regional Measles Elimination - Worldwide, 2000-2021
- PMID: 36417303
- PMCID: PMC9707362
- DOI: 10.15585/mmwr.mm7147a1
Progress Toward Regional Measles Elimination - Worldwide, 2000-2021
Abstract
All six World Health Organization (WHO) regions have committed to eliminating measles.* The Immunization Agenda 2021-2030 (IA2030)† aims to achieve the regional targets as a core indicator of impact and positions measles as the tracer of a health system's ability to deliver essential childhood vaccines. IA2030 highlights the importance of ensuring rigorous measles surveillance systems to document immunity gaps and achieve 95% coverage with 2 timely doses of measles-containing vaccine (MCV) among children. This report describes progress toward measles elimination during 2000-2021 and updates a previous report (1). During 2000-2021, estimated global coverage with a first MCV dose (MCV1) increased from 72% to a peak of 86% in 2019, but decreased during the COVID-19 pandemic to 83% in 2020 and to 81% in 2021, the lowest MCV1 coverage recorded since 2008. All countries conducted measles surveillance, but only 47 (35%) of 135 countries reporting discarded cases§ achieved the sensitivity indicator target of two or more discarded cases per 100,000 population in 2021, indicating surveillance system underperformance in certain countries. Annual reported measles incidence decreased 88% during 2000-2016, from 145 to 18 cases per 1 million population, then rebounded to 120 in 2019 during a global resurgence (2), before declining to 21 in 2020 and to 17 in 2021. Large and disruptive outbreaks were reported in 22 countries. During 2000-2021, the annual number of estimated measles deaths decreased 83%, from 761,000 to 128,000; an estimated 56 million measles deaths were averted by vaccination. To regain progress and achieve regional measles elimination targets during and after the COVID-19 pandemic, accelerating targeted efforts is necessary to reach all children with 2 MCV doses while implementing robust surveillance and identifying and closing immunity gaps to prevent cases and outbreaks.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Matt Ferrari reports grants from the Bill and Melinda Gates Foundation, the World Health Organization (WHO), and Gavi, The Vaccine Alliance to develop measles models. Allison Portnoy reports grant support from the Bill and Melinda Gates Foundation to develop models. Lee Lee Ho reports support as a consultant for WHO. No other potential conflicts of interest were disclosed.
Figures

Similar articles
-
Progress Toward Regional Measles Elimination - Worldwide, 2000-2020.MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1563-1569. doi: 10.15585/mmwr.mm7045a1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34758014 Free PMC article.
-
Progress Toward Measles Elimination - Worldwide, 2000-2022.MMWR Morb Mortal Wkly Rep. 2023 Nov 17;72(46):1262-1268. doi: 10.15585/mmwr.mm7246a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37971951 Free PMC article.
-
Progress Toward Regional Measles Elimination - Worldwide, 2000-2019.MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705. doi: 10.15585/mmwr.mm6945a6. MMWR Morb Mortal Wkly Rep. 2020. PMID: 33180759 Free PMC article.
-
Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018.Vaccine. 2021 Nov 17;39 Suppl 3:C89-C95. doi: 10.1016/j.vaccine.2021.03.095. Epub 2021 Apr 17. Vaccine. 2021. PMID: 33875267 Review.
-
Measles outbreak response immunization during the COVID-19 pandemic: lessons from Borno State, Nigeria.Pan Afr Med J. 2022 Feb 6;41:104. doi: 10.11604/pamj.2022.41.104.28162. eCollection 2022. Pan Afr Med J. 2022. PMID: 35432705 Free PMC article. Review.
Cited by
-
Genetic characterization of measles virus circulating in Iran, 2021-2023.BMC Infect Dis. 2025 Jan 23;25(1):108. doi: 10.1186/s12879-025-10473-w. BMC Infect Dis. 2025. PMID: 39849358 Free PMC article.
-
Measles virus: Continued outbreaks while striving for eradication.Virulence. 2024 Dec;15(1):2386022. doi: 10.1080/21505594.2024.2386022. Epub 2024 Aug 2. Virulence. 2024. PMID: 39092662 Free PMC article. No abstract available.
-
Antiviral activity of nitazoxanide against Morbillivirus infections.J Virus Erad. 2023 Nov 2;9(4):100353. doi: 10.1016/j.jve.2023.100353. eCollection 2023 Dec. J Virus Erad. 2023. PMID: 38028567 Free PMC article.
-
Progress Toward Measles Elimination - African Region, 2017-2021.MMWR Morb Mortal Wkly Rep. 2023 Sep 8;72(36):985-991. doi: 10.15585/mmwr.mm7236a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37676836 Free PMC article.
-
Measles Vaccine Coverage and Disease Outbreaks: A Systematic Review of the Early Impact of COVID-19 in Low and Lower-Middle Income Countries.Int J Public Health. 2024 Apr 25;69:1606997. doi: 10.3389/ijph.2024.1606997. eCollection 2024. Int J Public Health. 2024. PMID: 38725903 Free PMC article.
References
-
- Sbarra AN, Mosser JF, Jit M, Portnoy A. Estimating national-level measles case fatality ratios: an updated systematic review and modelling study. medRxiv [Preprint posted online October 5, 2022]. https://www.medrxiv.org/content/10.1101/2022.10.05.22280730v1 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical